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Abstract
This placebo-controlled, randomised, double-blind, cross-over human feeding studyaimed todetermine the prebiotic effect of agave fructans.A total of thirty-eight
volunteers completed this trial. The treatment consisted of 3 weeks’ supplementation with 5 g/d of prebiotic agave fructan (Predilife) or equivalent placebo (malto-
dextrin), followed by a 2-weekwashout period followingwhich subjects were crossed over to alternate the treatment arm for 3weeks followed bya 2-weekwashout.
Faecal samples were collected at baseline, on the last day of treatment (days 22 and 58) and washout (days 36 and 72), respectively. Changes in faecal bacterial
populations, SCFA and secretory IgA were assessed using ﬂuorescent in situ hybridisation, GC and ELISA, respectively. Bowel movements, stool consistencies,
abdominal comfort and mood changes were evaluated by a recorded daily questionnaire. In parallel, the effect of agave fructans on different regions of the colon
using a three-stage continuous culture simulator was studied. Predilife signiﬁcantly increased faecal biﬁdobacteria (log10 9·6 (SD 0·4)) and lactobacilli (log10
7·7 (SD 0·8)) compared with placebo (log10 9·2 (SD 0·4); P= 0·00) (log10 7·4 (SD 0·7); P = 0·000), respectively. No change was observed for other bacterial groups
tested, SCFA, secretory IgA, and PGE2 concentrations between the treatment and placebo. Denaturing gradient gel electrophoresis analysis indicated that bacterial
communities were randomly dispersed and no signiﬁcant differences were observed between Predilife and placebo treatments. The in vitromodels showed similar
increases in biﬁdobacterial and lactobacilli populations to that observed with the in vivo trial. To conclude, agave fructans are well tolerated in healthy human
subjects and increased biﬁdobacteria and lactobacilli numbers in vitro and in vivo but did not inﬂuence other products of fermentation.
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The importance of human gastrointestinal microbiota is
becoming increasingly recognised. Diet–microbe interactions
within the colon can result in a number of health beneﬁts: pro-
tection from invading pathogens, modulation of immune sys-
tem, production of vitamins and removal of carcinogens(1–3).
Selectively modulating the gut microbial activities is the basis
of the prebiotic concept that advocates targeting beneﬁcial
bacteria through non-viable food ingredients(4,5).
To date most attention has been focused on the prebiotic
potential of fructo-oligosaccharides and trans-galacto-
oligosaccharides. However, other ﬁbres including resistant
starches or dextrins, glucans, gums and pectins are also
increasingly being recognised as having prebiotic potential(6,7).
Fructans have been classiﬁed according to their structure and
fructosyl linkage as inulin, levan, graminans, neoseries levan and
neoseries graminans(8). The importance of inulin-type fructans
with linear β (2→ 1) linkages in human and bowel health is well
established both in vitro and in vivo(3,9). They have been consistently
associated with increases in populations of biﬁdobacteria and
lactobacilli and production of desirable fermentation endpro-
ducts(3,10,11). The rate and extent of fermentation of fructans is
inﬂuenced by the degree of polymerisation(12–14). Several studies
have investigated linear-chain fructans(3); however, there are few
data available on branched-chain fructans(15).
Agave plants have been historically known to be an import-
ant source of natural ﬁbre and alcoholic beverages in
Abbreviations: DGGE, denaturing gradient gel electrophoresis; FISH, ﬂuorescent in situ hybridisation; sIgA, secretory IgA; SS1, steady state 1; SS2, steady state 2.
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Mexico(8). Fructans from agave demonstrate wide diversity
with a complex and highly branched mixture of fructo-
oligosaccharides and fructans containing both β (2→ 1) and
β (2→ 6) linkages with internal (neoseries fructans) and exter-
nal (graminans fructans) glucose units(16). Different agave spe-
cies show variation in proportion of glucose polymerisations
and β (2→ 1) and β (2→ 6) linkages(17). Structural branching
of agave fructans may result in altered gut bacterial modulation
and fermentation proﬁle compared with inulin-type fructans.
Scanty information on the prebiotic properties of agave fruc-
tans justiﬁes the present study where fructans from Agave
tequilana Weber var. azul. (Predilife) were tested in an in vitro
gut model and human trial. A randomised, placebo-controlled,
cross-over design was chosen due to its robustness and
reduced intra-individual variability.
Fermentation of prebiotics is primarily anaerobic and thus
leads to the production of SCFA. The structure of carbohy-
drates and gut microﬂora inﬂuence SCFA proﬁles(7,14).
Therefore, in addition to studying the effect of agave fructans
on the composition of gut microbiota, SCFA concentrations
were also measured.
The prebiotic modulation of bacterial communities has been
shown to inﬂuence the host immune functions, including
up-regulation of immunoglobulins and reduction in prosta-
glandins(18,19). Consequently, the present study determined
levels of the two biomarkers: secretory IgA (sIgA) and PGE2.
Materials and methods
Test products
The prebiotic was provided to volunteers as sachets containing
5 g Predilife, a puriﬁed powder extracted from Agave tequilana
Weber var. azul. The preparation of Predilife has been
described previously(15). The placebo was a sachet containing
5 g of commercially available Maltodextrin Star DRI® 10
with Dextrose Equivalent 10 (Tate and Lyle). All test and pla-
cebo products were packaged and blinded by Bustar
Alimentos, Mexico. The products were only distinguishable
by the colour of the label. The nutritional information of the
products is given in Table 1.
Study design
The dietary intervention study was a double-blind, rando-
mised, placebo-controlled cross-over trial. At 14 d before
the start of the study, volunteers were asked to follow a
restricted diet; no consumption of pre- or probiotics was
allowed. A total of thirty-eight subjects were randomly allo-
cated into one of the two groups using an automated random-
isation sequence generated by a web-based tool
(randomisation.com). The ﬁrst group (n 19) consumed
Predilife (5 g/d) for 3 weeks followed by a washout period
for 2 weeks; they then consumed an equivalent placebo (5
g/d) for 3 weeks followed by a 2-week washout period. The
second group (n 19) received a placebo for the ﬁrst 3 weeks
followed by a 2-week washout period, Predilife for 3-weeks
followed by a 2-week washout (Fig. 1). No trial product was
consumed during the 2-week washout period. During the
intervention period, study subjects were instructed to consume
one sachet of the provided treatment by mixing the test pow-
der in 300 ml of water with breakfast every day. During the
trial, volunteers and researchers were unaware which product
was taken by which participant.
Subjects
A total of forty healthy human volunteers were recruited from
the Reading area of the UK to participate in the present study.
The subjects were recruited by advertising on notice boards
and emails were sent to all staff at Reading University. In add-
ition, letters were sent to volunteers registered with the
Sensory Dimensions (Reading, UK) database. Two volunteers
were prescribed antibiotics and were thus excluded from the
study, before the ﬁrst and the second feeding period, respect-
ively. For analysis purposes, thirty-eight volunteers, nineteen
males and nineteen females were included. Their mean age
was 35 (SD 8·0) years and average BMI was 24·1 (SD 3·0)
kg/m2. Written informed consent was obtained from all sub-
jects. The study was reviewed and approved by the University
of Reading Ethics Committee. The study protocol was con-
ducted according to guidelines in the Declaration of Helsinki.
Inclusion and exclusion criteria
Inclusion criteria. Inclusion criteria were a signed consent
form, aged 18–50 years inclusive, BMI 18–30 kg/m2
inclusive, non-smoking and good general health.
Exclusion criteria. Volunteers were excluded from the trial if
there was evidence of physical or mental disease or major
surgery. Volunteers with a history of drug or alcohol abuse,
severe allergy, abnormal drug reaction, pregnant, lactating or
planning pregnancy were excluded from the study. Intake of
an experimental drug within 4 weeks before the study,
former participation in a probiotics, prebiotics or laxative
trial within the previous 3 months, use of antibiotics within
the previous 6 months, chronic constipation or other
chronic gastrointestinal complaints (for example, irritable
bowel syndrome) were all exclusion criteria.
Table 1. Nutritional information of placebo and Predilife
Nutrients (per 5 g dose) Placebo* Predilife†
Energy
kJ 66·32 34·12
kcal 15·6 8·15
Protein (g) 0 Trace
Carbohydrates (g) 3·90 4·90
Sugars (g) 0·78 0·20
Fat (g) 0 Trace
SFA (g) 0 0
Cholesterol (mg) 0 0
Dietary fibre (g) 0 4·70
Of which fructans (inulin) (g) 0 4·70
Na (mg) 8·59 2·50
* Placebo ingredients: Maltodextrin Star DRI 10, orange flavour, orange colour,
sucralose.
† Predilife ingredients: Predilife agave fructans, orange flavour, orange colour,
sucralose.
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Diet and medication requirements during the trial
Intake of prebiotics, probiotics and drugs active on gastro-
intestinal motility, antibiotic treatment or any class of laxatives
were not permitted. Subjects were not allowed to participate in
any other nutritional or pharmaceutical trials during the study.
Any medication taken was recorded in volunteer diaries.
Volunteers were instructed not to alter their usual diet or
ﬂuid intake during the study.
Volunteer diaries
Volunteers were asked to keep diaries throughout the study to
record stool frequency and consistency, abdominal pain, intes-
tinal bloating and ﬂatulence on a daily basis. Energetic status,
happiness, alertness and stress levels as compared with normal
were also recorded. Any concomitant medication, adverse
events and failure to consume any treatments were also
recorded by the volunteers.
In addition, volunteers were asked to record the time of
consumption of the product for measuring compliance.
Volunteers were instructed to return any unused sachets at
the end of the intervention. They were considered compliant
for the product if they consumed at least 90 % of the product
over the 3-week intervention. They were also asked not to alter
their usual diet and ﬂuid intake and record changes, if any.
Stool sample collection and processing
Freshlyvoided stool samples collected inplasticpotswere stored in
an anaerobic cabinet (10%H2, 10%CO2, 80%N2; DonWhitley
Scientiﬁc)at 37°Candprocessedwithin2 hofvoiding.Faecal sam-
ples were collected before and after treatment with either agave
fructan or maltodextrin and washout on days 0, 22, 36, 58 and
72 (Fig. 1). Samples were diluted 1:10 (w/w) in PBS (0·1 M, pH
7·0) and homogenised in a stomacher (Seward) at normal speed
for 2 min. The faecal slurry was transferred to 50 ml sterile plastic
centrifuge tubes containing 2 g glass beads (diameter 5 mm) and
vortexed for 30 s. Samples were then centrifuged at 400 g for 5
min at room temperature and supernatant fractions processed
for ﬂuorescent in situ hybridisation (FISH) and SCFA analysis.
The pellet was resuspended in 500 µl of autoclaved PBS–glycerol
(1:1) forDNA extraction. A quantity of 1 g of faeces was collected
in microcentrifuge tubes and stored at –20°C for ELISA.
Fluorescent in situ hybridisation
Synthetic oligonucleotide probes targeting speciﬁc regions of
the 16S rRNA labelled with ﬂuorescent Cy 3 were utilised
for enumeration of bacterial populations. The faecal supernatant
fractions obtained as described abovewereﬁxed in 4% (w/v) par-
aformaldehyde and hybridised with appropriate probes as
described by Vulevic et al.(18). The probes used were Bif164(20),
Lab158(21), Erec482(22), Ato291(23), Bac303(24), Rrec584(22),
Eco1531(25) and Eub338 mix(26) speciﬁc for biﬁdobacteria,
Lactobacillus/Enterococcus spp., Eubacterium/Clostridium coccoides
group, Atopobium spp., Bacteroides, Roseburia/Eubacterium rectale
spp., Escherichia coli and total bacteria, respectively. Slides were
examined under an epiﬂuorescence microscope (Eclipse 400;
Nikon) using the Fluor 100 lens. At least ﬁfteen random ﬁelds
of view were counted for each well and microbial counts
expressed as log 10 bacterial cells per g dry weight faeces.
SCFA analyses
Fermentation output was determined by measuring changes in
faecal SCFA concentrations in the collected supernatant fractions.
Acetate, propionate, butyrate, isobutyrate, valerate, isovalerate
and caproate were analysed in the collected samples as their
salyl derivatives by GC(27). The organic acids were extracted by
addition of 0·5 ml concentrated hydrochloric acid and 2 ml
diethyl ether. N-tert-butyldimethylsilyl-N-methyltriﬂuoroaceta-
mide (MTBSTFA) was used to derivatise the samples at 80°C
for 20 min. Samples were then run through a 5890 series II GC
system (Hewlett Packard) ﬁtted with a SGE-HT5 (0·32 mm×
25 m× 0·1 µm) (J&WScientiﬁc) and aﬂame ionisation detector.
Injector, oven and detector were set at 275, 250 and 275°C,
respectively. A quantity of 1 µl of each sample was injected with
a run time of 10 min. Peaks were integrated using the Atlas Lab
managing software (Thermo Lab Systems). Fatty acid concentra-
tions were calculated in mmol/l by comparing their peak areas
with standards.
Immunological analysis
Faecal sIgA (OxfordBiosystems) and PGE2 (NeogenCorp.) were
measured by ELISAusing commercially available kits and instruc-
tions provided by the manufacturers. Absorption was measured
using an ELISA reader (GENios; Tecan). A calibration curve
was constructed using a range of standards which were then
used to assay the immunological marker in each of the samples.
The results were expressed as µg/g or pg/g faeces (wet weight).
Bacterial DNA extraction and PCR–denaturing gradient gel
electrophoresis
Bacterial cell pellets collected after centrifugation and resus-
pension in PBS–glycerol, frozen at –20°C, were thawed on
Fig. 1. Study design.
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ice. Bacterial DNA was extracted using the FastDNA Spin kit
(Qbiogene) according to the manufacturer’s instructions.
DNA was resuspended in 50 µl of sterile water, quantiﬁed
using a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies) and stored at –20°C. PCR using universal P2
and P3 primers was performed as previously reported(28).
Approximately 5 µl of each PCR product were applied
to denaturing gradient gel electrophoresis (DGGE) using
a VWR CTV400-DGGE unit (VWR International). The poly-
acrylamide gel (acrylamide-bisacrylamide, 37·5:1; Bio-Rad) had
a linear denaturing gradient of 30–70 %. Electrophoresis was
run in 0·5× Tris acetate EDTA (TAE) buffer (made from 50×
concentrate; Fischer) at 100 V and 60°C for 16 h. Gels were
silver stained and scanned using a Cannon scanner (Lide 50;
Cannon) and analysed using FPQuest Software version 4.5
(Bio-Rad). In order to compensate for gel-to-gel differences
and distortion due to electrophoresis, DGGE patterns were
aligned and normalised using a reference ladder composed
of baseline sample from one volunteer. After normalisation,
bands from each sample were deﬁned using appropriate densi-
tometric curves. Bands constituting less than 1 % of the total
band area were omitted from further analysis. Similarity
between DGGE proﬁles was calculated using the Pearson cor-
relation. Clustering of proﬁles was done using the unweighted
pair-group method using arithmetic average.
Three-stage continuous culture model
Parallel to the human study, in vitro testing was carried out
using a three-stage continuous culture model of the human
colon(29). The model consisted of three glass vessels with
increasing working volume aligned in series. The ﬁrst vessel
simulated the proximal colon and had an operating volume
of 280 ml and was fed with the growth medium. The second
vessel, simulating the transverse colon, had an operating vol-
ume of 300 ml and was fed from the overﬂow of the ﬁrst ves-
sel. The third vessel simulating the distal colon had an
operating volume of 320 ml and was fed from the overﬂow
of the second vessel. Culture ﬂuid from the third vessel was
vented into a waste container. All vessels were continuously
stirred and maintained at 37°C by a circulating water jacket.
The pH of the vessels was maintained at 5·4, 6·2 and 6·7
for vessels 1, 2 and 3, respectively, by using pH controllers
(Electrolab) pumping in 0·5 M-HCl/NaOH solutions as
required. The system was kept anaerobic by continuously spar-
ging with O2-free N2 through the liquid (about 15 ml/min) in
all vessels. The culturemediumconsisted of the following compo-
nents (g/l): starch 5; peptonewater 5; yeast extract 4·5; tryptone 5;
NaCl 4·5; KCl 4·5; mucin 4; casein 3; pectin 2; xylan 2; arabino-
galactan 2; NaHCO3 1·5; MgSO4.7H2O 1·25; guar gum 1; inulin
1; cysteine HCl 0·8; KH2PO4 0·5; K2HPO4 0·5; bile salts no. 3
0·4; CaCl2.6H2O 0·15; haemin 0·05; vitamin K 0·01;
FeSO4.7H2O0·005;Tween801 ml.Aquantityof 4 ml rezarsurin
was added at a concentration of 0·025 % (w/v) to the medium as
an indicator of anaerobicity.
Faecal inoculum was collected from one healthy human vol-
unteer, aged 22 years, who had not taken antibiotics 6 months
before sample collection. The sample was diluted 1:5 (w/v) in
PBS (0·1 M; pH 7·4) and homogenised in a stomacher
(Seward) for 2 min. Each vessel was inoculated with 100 ml
fresh faecal slurry. After 24 h of inoculation, the medium
ﬂow was initiated and the system ran for eight full volume
turnovers (16 d) to allow steady state 1 (SS1) to be achieved.
At SS1, 5 ml samples were collected from each vessel for
three consecutive days and centrifuged at 13 000 g for 10
min. The supernatant fractions were ﬁxed in 4 % (w/v) paraf-
ormaldehyde for FISH analysis. For SCFA analysis the super-
natant fractions were stored at –20°C and analysed by GC.
Total bacterial counts and SCFA concentrations were analysed
over three consecutive days to conﬁrm SS1. Three gut models
were run using faecal samples from the same donor, namely
Synergy 1 (a prebiotic – fructo-oligosaccharide inulin mix
from Orafti), Predilife and maltodextrin. After SS1, each of
the test products was added to the ﬁrst vessel in 5 g doses
each day until steady state 2 (SS2) was reached after further
eight volume turnovers (33 d). Samples were obtained as
above for measuring any changes in gut microbiota using
FISH and SCFA analysis for three consecutive days until a sec-
ond steady state (SS2) was established.
Statistical analyses
A total of forty healthy human volunteers were recruited based
on statistical power calculation. The sample size was deter-
mined to detect a 0·5 log10 change in biﬁdobacterial counts
with power set at 0·9, and a signiﬁcance level of 0·05 based
on our previous prebiotic studies in human volunteers con-
ducted with the same microbiological techniques(30,31).
Statistical analysis was performed on bacterial counts (log10
cells/g faeces) and fermentation characteristics using SPSS soft-
ware (version 19; SPSS Inc.). Data from volunteers that com-
pleted the intervention were included in the analysis. Statistical
signiﬁcance of the overall treatment effect was judged using linear
mixed models with compound symmetry repeated covariance
format.Treatment, period and sequencewereﬁxed effects, period
was a repeated measure and participant was a random effect. All
models were adjusted for age, sex, BMI, baseline values, sequence
and period. Treatment, sequence and period terms were used to
test for the presence of a carryover effect. In exploratory terms,
there were no signiﬁcant period order effects noted. The effects
of age, sex or BMI on treatment were assessed in each model
by inserting an interaction between treatment and each of the
terms one at a time. Stratiﬁed analyses were performed if either
of the interactions was signiﬁcant. Student’s t tests were used to
compare the pre-treatment and post-treatment period measure-
ments within each treatment, bowel habits, gastrointestinal
symptoms and mood data. Data for DGGE were analysed by
using FPQuest Software version 4.5 (Bio-Rad). For all analyses,
P < 0·05 indicated statistical signiﬁcance.
Results
Subject characteristics and compliance
In total, forty volunteers entered the cross-over study (twenty
female, twenty males); of these, two were excluded due to
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antibiotic intake. Therefore, a total of thirty-eight volunteers
(nineteen female, nineteen males) aged 20–49 years (average
age 35 (SD 8·0) years) with average BMI 24·1 (SD 3·0) kg/m2
completed the human trial. Compliance for product intake,
as assessed by diary data of regular consumption of sachets
and returned unused sachets, was good (95–100 %). None
of the volunteers indicated alterations in diet or ﬂuid intake
and were thus complaint.
Medication and adverse events
Volunteers had consumed a variety of over-the-counter drugs
such as cold and ﬂu remedies, anti-allergy tablets and painkil-
lers. No extremes were observed and the level of medication
was judged as representative of a typical UK population.
Among adverse events recorded in volunteer diaries, head-
ache, cough and colds, fever, backache, toothache were
recorded over the two treatment and washout periods. No ser-
ious adverse events were recorded.
Faecal microbiota
Changes in bacterial numbers are shown in Table 2.
Consumption of Predilife increased biﬁdobacterial numbers
(log10 9·6 (SD 0·4)) compared with placebo (log10 9·2 (SD
0·4)). Levels of biﬁdobacteria returned to approximate base-
line levels (log10 9·2 (SD 0·2)) (P < 0·001) 2 weeks after inter-
vention was stopped.
Lactobacilli/enterococci numbers also signiﬁcantly
increased following Predilife treatment (log10 7·7 (SD 0·8)) as
compared with placebo (log10 7·6 (SD 0·6)) (Table 2).
For all the other groups enumerated, no signiﬁcant differ-
ences were observed.
Analysis of bowel habits, intestinal comfort and mood
Table 3 summarises data on bowel habits, intestinal comfort
and mood. No signiﬁcant differences were recorded in the
mean daily stool frequencies and consistencies with either
treatment. However, some volunteers did report a borderline
signiﬁcant trend formore formed stools and decrease in constipa-
tion after consumption of Predilife (P= 0·08). No signiﬁcant
change in abdominal pain was observed. Predilife consumption
led to increased intestinal bloating (mild to moderate) compared
withmaltodextrin (P< 0·05). No signiﬁcant increase in ﬂatulence
was observed after consumption of Predilife compared with pla-
cebo. In addition, no signiﬁcant differences in mood scores were
observed with either treatment.
SCFA analysis
Faecal SCFA concentrations were similar following Predilife
and maltodextrin interventions (Table 4).
Faecal secretory IgA and PGE2 levels
There were no signiﬁcant differences in faecal sIgA concentra-
tions or PGE2 levels when consuming Predilife or placebo
(Table 5).
Denaturing gradient gel electrophoresis
DGGE results demonstrated that inter-individual variability
was a greater variable than the typology of treatment. For
group 1 with Predilife as the ﬁrst treatment, nine of the nine-
teen subject samples were clustered along the intervention. For
group 2 which received maltodextrin as the ﬁrst treatment,
only three of the nineteen subject samples were grouped
along the intervention. The overall ﬁngerprint of the gut
microbiota did not differ signiﬁcantly and most samples
were randomly dispersed (Fig. 2).
Microflora and SCFA changes in three-stage continuous
culture models
To support the in vivo observations, we also investigated the
effect of agave fructans on the growth of faecal bacteria in a
three-stage continuous culture system. The changes in biﬁdo-
bacterial and lactobacilli/enterococci populations measured by
FISH in the three vessels at the two steady states (SS1 and SS2)
Table 2. Faecal bacterial numbers (log10 cells/g faeces) determined in thirty-eight volunteers by fluorescence in situ hybridisation in the placebo-controlled,
double-blind, cross-over human feeding study investigating the effects of Predilife (5 g/d) as compared with the placebo maltodextrin (5 g/d)
(Mean values and standard deviations)
Predilife Maltodextrin
Baseline Treatment Baseline Treatment
Bacterial group Mean SD Mean SD Mean SD Mean SD
Total bacteria 10·8 0·2 10·8 0·2 10·8 0·2 10·8 0·2
Atopobium 9·3 0·4 9·3 0·4 9·3 0·3 9·4 0·4
Bacteroides 9·9 0·1 9·9 0·1 9·9 0·1 9·9 0·1
Bifidobacterium spp. 9·2 0·4 9·6***†† 0·4 9·2 0·3 9·2 0·4
Eubacterium rectale/Clostridium coccoides 10·1 0·2 10·2 0·3 10·1 0·2 10·1 0·4
Clostridium histolyticum group 7·8 0·3 7·9 0·3 7·9 0·3 7·9 0·3
Lactobacillus/Enterococcus spp. 7·3 0·6 7·7***††† 0·8 7·3 0·6 7·4 0·6
Escherichia coli 7·5 0·3 7·4 0·3 7·5 0·3 7·4 0·3
Roseburia/Eubacteria group 9·7 0·2 9·7 0·2 9·7 0·2 9·7 0·2
*** Mean value was significantly different from that for maltodextrin (P < 0·001).
Mean value was significantly different from that at baseline: †† P < 0·01, ††† P < 0·001.
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are shown in Table 6. Signiﬁcant increases in numbers of
Biﬁdobacterium spp. and Lactobacillus/Enterococcus group were
observed at SS2 in all three vessels after feeding with
Synergy 1 and Predilife. No changes in bacterial numbers
were observed with maltodextrin.
The production of SCFA in the presence of Predilife,
Synergy 1 and maltodextrin in the three-stage continuous cul-
ture models is shown in Table 7. Concentrations of acetate,
propionate, butyrate and total fatty acids increased signiﬁcantly
in all three vessels upon Predilife and Synergy 1 dosing.
Table 3. Summary of bowel habit, intestinal comfort and general mood data recorded on a daily basis in volunteer diaries throughout the study‡
(Mean values and standard deviations)
Predilife Maltodextrin
Baseline Treatment Baseline Treatment
Mean SD Mean SD Mean SD Mean SD
Stool frequency (n/d) 1·2 0·4 1·4 0·5 1·1 0·3 1·3 0·4
Stool consistency
Hard 6·9 15·2 6·6 11·6 7·3 11·4 7·9 17·1
Formed 73·4 22·4 55·0 34·9 74·1 25·1 71·3 27·0
Soft 20·1 25·1 38·5 36·4 16·9 23·2 20·5 22·1
Abdominal pain
None 81·2 20·4 84·5 26·7 80·1 15·3 89·5 17·8
Mild 15·2 18·1 12·4 22·7 16·2 8·3 7·2 9·9
Moderate 2·1 15·2 2·5 11·7 2·8 4·1 1·8 5·7
Severe 0·2 1·3 0·6 3·9 0·9 2·1 1·4 8·5
Intestinal bloating
None 85·2 18·2 79·7*† 29·0 84·1 25·1 84·2 27·7
Mild 10·1 11·8 14·4*† 18·9 11·2 20·3 9·9 16·1
Moderate 2·7 10·1 5·6* 19·4 2·5 7·8 4·8 13·9
Severe 0·3 0 0·3 1·5 0 0 1·1 4·9
Flatulence
None 68·8 32·6 51·2 38·9 66·5 30·1 63·2 37·5
Mild 28·2 31·0 31·7 27·5 28·7 17·1 26·7 26·2
Moderate 5·9 8·9 13·7 21·3 4·7 8·2 8·4 14·8
Severe 0·8 2·3 3·6 9·8 0·3 5·7 1·6 5·9
Mood changes
Happy
Less than normal 8·1 18·1 5·1 8·8 4·2 18·1 4·2 9·9
Normal 88·2 12·2 89·2 17·0 90·1 15·2 93·1 13·7
More than normal 2·0 9·4 6·8 15·4 6·4 10·2 2·7 6·5
Alert
Less than normal 4·5 9·1 3·6 9·6 3·0 8·0 2·9 6·6
Normal 95·2 19·2 93·6 14·2 94·2 18·1 95·5 9·6
More than normal 0 2·1 2·8 11·1 2·0 4·8 1·6 5·7
Energetic
Less than normal 5·1 12·1 6·5 11·9 5·0 15·2 4·8 10·3
Normal 90·3 15·8 90·4 14·8 91·4 16·1 92·4 12·7
More than normal 5·1 7·6 3·13 8·74 4·6 6·0 3·9 7·6
Stressed
Less than normal 3·2 8·2 4·01 13·1 0·9 2·8 1·4 4·1
Normal 89·1 19·2 90·10 18·3 96·1 15·4 94·6 14·7
More than normal 7·5 5·4 5·89 12·1 2·7 4·6 4·0 13·0
* Mean value was significantly different from that for maltodextrin (P < 0·05).
† Mean value was significantly different from that at baseline (P < 0·05).
‡ Percentage coverage of each category over the total number of responses per volunteer was determined.
Table 4. SCFA profiles (mmol/g faeces) determined by GC from the placebo-controlled, double-blind, cross-over human feeding study with thirty-eight
healthy human volunteers investigating the effects of Predilife (5 g/d) as compared with the placebo maltodextrin (5 g/d)
(Mean values and standard deviations)
Predilife Maltodextrin
Baseline Treatment Baseline Treatment
SCFA Mean SD Mean SD Mean SD Mean SD
Acetate 0·7 0·4 0·8 0·7 0·6 0·3 0·7 0·4
Propionate 0·3 0·2 0·3 0·3 0·3 0·2 0·3 0·3
Butyrate 0·2 0·1 0·2 0·2 0·2 0·1 0·2 0·5
Total 1·2 1·3 1·1 1·2
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However, SCFA in the presence of maltodextrin did not differ
signiﬁcantly. Also, no signiﬁcant differences were observed for
other SCFA produced.
Discussion
This is the ﬁrst randomised, cross-over, double-blind clinical
trial that has examined the effect of branched agave fructan
on bacterial populations, SCFA, sIgA, PGE2, bowel habits
and mood changes in healthy human volunteers.
Agave fructans increased biﬁdobacteria by 0·4 log in compari-
son with placebo (Table 2). The increase was similar to that
observed with other intervention studies which report increases
between 0·5 and 1·0 log biﬁdobacterial counts(3,32–34). In a few
reports where higher biﬁdobacterial numbers have been
reported, higher doses of fructans were consumed(35,36). In add-
ition, the magnitude of change in biﬁdobacterial numbers also
depends on initial levels(30,32–34). Biﬁdobacterial numbers
returned to baseline levels at the end of washout similar to pre-
vious studies(33,34,36–38).
In addition to the increase in biﬁdobacterial counts, there
was an increase in the lactobacilli/enterococci group: 0·4
log10 cells/g faeces compared with placebo (Table 2). This is
similar to previous reports with fructans from chicory(3) and
globe artichoke(32) where increases in lactobacilli/enterococci
have been observed. There have been a few reports with fruc-
tans from Jerusalem artichoke(33,35) or chicory(34) where either
no or less change in the lactobacilli/enterococci group has
been reported.
There was no change in the numbers of total bacteria,
Atopobium, Bacteroides, Eubacterium rectale/Clostridium coccoides,
E. coli and Roseburia/Eubacteria group. This contrasts with
decreases in levels of Bacteroides and clostridia reported in
other studies with globe artichoke and Jerusalem artichoke
inulin(32,35). Overall, there were no signiﬁcant differences in
faecal SCFA concentrations. It is recognised that over 95 %
of SCFA produced in the human large intestine is absorbed,
with only a small proportion is excreted in faeces(31–33,39).
Parallel to the human trial, the dynamics of bacterial growth
and fermentation induced in the presence of Predilife was
assessed and compared with Synergy 1 and maltodextrin
using a three-stage continuous culture models. Both agave-
and chicory-derived inulin stimulated the growth of biﬁdobac-
teria and lactobacilli to a similar extent (0·4–0·6 log10 cells/ml)
as with the human trial data. However, the SCFA data indi-
cated an increased production of acetate, propionate and
butyrate, which contrasted with the human study data. This
presumably reﬂected the fact that SCFA were rapidly absorbed
by the human colon(35). It may also suggest that the fructans
were rapidly fermented in the proximal colon and thus not
excreted in the faeces(40). Further, the bacterial groups that
were active agave degraders do not produce butyrate. This
can be explained by substantial information on cross-feeding
of fermentation products by gut microbiota(41,42). The results
from the in vivo and in vitro trials with branched agave fructans
were consistent with those for linear fructans(3,32–34). This
Table 5. Changes in faecal secretory IgA (sIgA) and PGE2 levels in the placebo-controlled, double-blind, cross-over human feeding study with thirty-eight
healthy human volunteers investigating the effects of Predilife (5 g/d) as compared with the placebo maltodextrin (5 g/d)
(Mean values and standard deviations)
Baseline Predilife treatment Maltodextrin treatment
Immunological parameter Mean SD Mean SD Mean SD
Faecal sIgA (µg/g) 628·3 80·8 623·3 80·8 628·3 80·9
Faecal PGE2 (pg/g) 1124·9 143·7 984·8 132·1 1056·3 89·3
Fig. 2. Cluster analysis: dendrogram of electrophoretic band pattern of sub-
jects obtained using universal primers in faecal samples collected at baseline
(S1), and during intake of Predilife (S2) and maltodextrin (S4).
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indicates that structural differences between linear inulin type
(β2-1 linkages) and branched agave (β2-1; 2-6 linkages) fruc-
tans do not seem to inﬂuence modulation of gut microbiota
or their fermentation proﬁles.
As the extent of fermentation is also inﬂuenced by the
degree of polymerisation, it may be suggested that the lower
chain lengths in Predilife (degree of polymerisation 3–30)(15)
may contribute to the prebiotic effect. Further investigation
of the fractions of agave fructans to identify chain lengths
responsible for these effects may be warranted.
The effect of Predilife consumption on bowel habits and
quality of life of subjects was assessed during the trial.
Predilife did not inﬂuence the measured aspects of quality of
life: mood, alertness, energy and stress levels. However, effects
on bowel habits were more profound. No signiﬁcant changes
in stool frequency or consistencies were observed. There was
Table 6. Bacterial enumeration using fluorescent in situ hybridisation in the three-stage continuous system during two steady states for Predilife, Synergy 1
and maltodextrin†
(Mean values and standard deviations)
Bifidobacterium spp. Lactobacillus spp.
Substrate Steady state Vessel no. Mean SD Mean SD
Predilife 1 1 7·7 0·1 6·4 0·1
2 7·6 0·1 6·5 0·1
3 7·6 0·2 6·7 0·2
2 1 8·3* 0·1 7·0* 0·1
2 8·2* 0·1 6·9* 0·1
3 7·8* 0·0 6·7* 0·0
Synergy 1 1 1 7·7 0·2 6·5 0·2
2 7·8 0·1 6·7 0·1
3 7·9 0·1 6·6 0·1
2 1 8·2* 0·2 6·9* 0·2
2 8·2* 0·1 6·8* 0·1
3 8·1* 0·1 6·5* 0·1
Maltodextrin 1 1 7·7 0·2 6·7 0·2
2 7·9 0·1 6·6 0·1
3 7·9 0·1 6·6 0·1
2 1 7·7 0·2 6·5 0·2
2 7·8 0·1 6·6 0·4
3 7·9 0·1 6·6 0·1
* Mean value was significantly from that during steady state 1 (P < 0·05).
† Bacterial numbers were measured as log10 cells/ml. Measurements were performed on three consecutive days during each steady state (after feeding the model with the
respective substrate). Data from the 3 d were averaged.
Table 7. SCFA concentrations in the three-stage continuous system during two steady states for Predilife, Synergy 1 and maltodextrin†
(Mean values and standard deviations)
Acetic acid Propionic acid Butyric acid Total SCFA
Substrate Steady state Vessel no. Mean SD Mean SD Mean SD Mean SD
Predilife 1 1 0·6 0·2 1·2 0·1 0·0 0·1 1·8 0·1
2 0·9 0·1 0·5 0·0 0·1 0·0 1·5 0·0
3 0·3 0·1 0·1 0·00 0·1 0·0 0·4 0·0
2 1 31·8* 0·1 10·2* 0·0 7·1* 0·0 49·1* 0·3
2 27·0* 0·0 8·2* 0·0 5·2* 0·0 40·4* 0·0
3 12·5* 0·0 12·5* 0·0 4·2* 0·0 28·2* 0·1
Synergy 1 1 1 1·1 0·1 0·5 0·1 0·2 0·2 1·8 0·1
2 1·6 0·1 0·2 0·1 0·1 0·1 2·0 0·1
3 0·8 0·2 1·3 0·2 0·1 0·8 3·2 0·8
2 1 28·5* 0·1 12·8* 0·1 5·9* 0·1 47·9* 0·1
2 15·2* 0·1 13·6* 0·1 4·6* 0·1 33·6* 0·1
3 10·0* 0·0 5·9* 0·2 2·8* 0·0 18·9* 0·0
Maltodextrin 1 1 2·0 0·0 2·2 0·0 1·2 0·0 11·4 0·0
2 1·2 0·0 1·0 0·0 1·5 0·0 5·6 0·0
3 1·7 0·0 1·5 0·0 1·0 0·1 2·9 0·0
2 1 2·1 0·0 1·0 0·0 0·04 0·1 11·2 0·0
2 1·1 0·0 1·0 0·0 1·0 0·0 5·5 0·0
3 1·2 0·0 1·1 0·0 1·0 0·0 3·2 0·0
* Mean value was significantly from that during steady state 1 (P < 0·05).
† SCFA concentrations were measured as mM. Measurements were performed on three consecutive days during each steady state (after feeding the model with the respective
substrate). Data from the 3 d were averaged.
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no signiﬁcant increase in abdominal pain levels. However, sig-
niﬁcantly increased intestinal bloating (mild to moderate) and
ﬂatulence (mild and severe) were recorded by subjects when
consuming Predilife. Several studies have reported stimulation
of bowel movements, and increased bloating and ﬂatulence on
ingestion of fructans(32,33,35,36,39,43,44). The formation of H2,
which is a metabolic endproduct of bacterial fermentation in
the colon, is a major cause of ﬂatulence. However, it must be
noted that biﬁdobacteria, the numbers of which were signiﬁcantly
increased on intake of Predilife, are not considered to be produ-
cers of H2, or any other gas. In contrast, clostridia are proliﬁc
gas producers, but did not show any signiﬁcant increase upon
ingestion of Predilife. Thus, the relationship between speciﬁc
intestinal bacteria and gas production remains to be clariﬁed(35,45).
The effect of Predilife consumption on the faecal immune
markers sIgA and PGE2 was also determined. No change in
these markers was observed. Faecal sIgA is primarily involved
in mucosal immunity and protein barrier function against
infection(46). PGE2 plays a role in immune modulation and
normal physiological gastrointestinal functions including cyto-
protection(47). In previous studies with pre- and probiotics,
increases in immune markers(46,47), unchanged levels(19,48,49)
and decreased levels have been reported(19,50). Many factors
including stress, exercise and dietary fat may have an impact
on these immune parameters(19,51,52), therefore resulting in
variable trends. DGGE analyses, which allow a semi-
qualitative evaluation of the ﬁngerprint of the gut microbiota
of subjects enrolled in the study, indicated that the treatment
did not signiﬁcantly modify the overall ﬁngerprint of the gut
microbiota to a great extent (to overcome the inter-individual
differences). No signiﬁcant differences were indicated between
Predilife and maltodextrin.
In conclusion, in vivo and in vitro data conﬁrm the prebiotic
effectiveness of agave fructans as observed by selective
increases in biﬁdobacteria and lactobacilli populations. Agave
represents an important alternative prebiotic to other sources
of fructans. In addition, due to its good solubility in cold
water, it can be readily incorporated into beverages, dairy pro-
ducts, cheese and yogurts.
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